Form 4: ResMed CEO Sells Shares After Option Exercise

ResMed Inc. CEO Michael J. Farrell exercised stock options and subsequently sold 8,009 shares of common stock under a pre-arranged 10b5-1 plan.

Summary

• Michael J. Farrell, Chief Executive Officer of ResMed Inc., reported changes in his beneficial ownership of company securities.
• On August 7, 2025, Mr. Farrell acquired 8,009 shares of ResMed Common Stock by exercising stock options at a price of $101.64 per share.
• Concurrently, on August 7, 2025, he disposed of 8,009 shares of ResMed Common Stock through a sale at a weighted average price of $279.4829 per share.
• The sale price ranged from $277.76 to $282.66 per share.
• Both the acquisition and disposition transactions were conducted under a Rule 10b5-1 plan, which was adopted on October 31, 2024.
• Following these transactions, Mr. Farrell directly owns 455,503 shares of ResMed Common Stock.
• Additionally, 2,090 shares are indirectly owned through the Lisette and Michael Farrell Family Trust.
• Mr. Farrell holds 24,029 unexercised ResMed Common Stock Options, which became exercisable starting November 11, 2019, vesting 1/3 per year, and expire on November 14, 2025.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine, pre-planned insider transaction (exercise of options and subsequent sale of shares) under a 10b5-1 plan. It does not reflect new company performance or strategic shifts.

Positives

• The CEO realized a significant profit from exercising options at $101.64 and selling shares at a weighted average of $279.4829, indicating a substantial gain on the exercised shares.
• The transactions were conducted under a Rule 10b5-1 plan, which suggests a pre-scheduled and orderly disposition of shares, reducing concerns about opportunistic insider trading.

Negatives

• The sale of shares by the Chief Executive Officer, even if pre-planned, reduces his direct ownership stake in the company.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding the company's future performance or strategic outlook.

Management Comments

• The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.

Industry Context

This filing is a routine insider transaction report and does not contain information related to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: The sale by the CEO slightly reduces his direct ownership, but as a pre-planned transaction, it is generally not viewed as a negative signal.
• Employees: No direct impact mentioned.

Next Steps

• Remaining options will continue to vest at 1/3 per year until their expiration on November 14, 2025.

Key Dates

Keywords

ResMed, RMD, Michael J. Farrell, CEO, Insider Transaction, Stock Options, 10b5-1 Plan, Beneficial Ownership, SEC Form 4